This record was last updated July 22, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In a population of adult patients followed for Crohn's disease, who had previously agreed to replace Stelara® with a biosimilar of ustekinumab (Uzpruvo®) and were followed over a period of 12 months under usual medical practice conditions.
* Main objective: To assess the maintenance of the biosimilar of ustekinumab at 12 months without returning to the reference treatment
* Secondary objectives:
* To describe the factors associated with the maintenance of the biosimilar
* To evaluate the evolution of patients' quality of life
* To assess the rate of maintenance of clinical remission at M12
* To describe the acceptability of the biosimilar treatment by patients
* To evaluate patient satisfaction
* To evaluate treatment tolerance
* To describe the reasons for treatment discontinuation that occurred during follow-up
* To describe the profile of patients who discontinued treatment upon their request.